Patient factors and quality of life outcomes differ among four subgroups of oncology patients based on symptom occurrence

Quality of life and psychological distress are differentially associated with distinct symptom‐functional states in terminally ill cancer patients' last year of life

“…Our finding that terminally ill cancer patients in the worst symptom‐functional states had significant and highly likely, clinically meaningful lower QOL than patients in the best state of mild symptom distress with high functioning (state 1, Table ) is consistent with previous reports . Indeed, cross‐sectional latent class analysis found that oncology patients in the class with highest physical or psychological symptom occurrence had the lowest QOL.…”

“…32 Our finding that terminally ill cancer patients in the worst symptom-functional states had significant and highly likely, clinically meaningful lower QOL than patients in the best state of mild symptom distress with high functioning (state 1, Table 2) is consistent with previous reports. 4,35 Indeed, cross-sectional latent class analysis found that oncology patients in the class with highest physical 4,35 or psychological 35 symptom occurrence had the lowest QOL. However, we failed to show any differential associations among the 4 worst symptom-functional states and QOL, except for the borderline worse QOL for patients with severe-profound symptom distress with moderate-profound functional impairment (states 3 and 5) than for those with moderate symptom distress and mild functional impairment (state 2) (Table 3).…”

Symptom burden and patient characteristics: Association with quality of life in patients with head and neck cancer undergoing radiotherapy

“…This study is part of a larger, longitudinal study of symptoms and QOL in 534 oncology patients . Study procedures were described in detail elsewhere .…”

“…This study is part of a larger, longitudinal study of symptoms and QOL in 534 oncology patients. 38 Study procedures were described in detail elsewhere. 39,40 In brief, patients with HNC were recruited before RT at the Norwegian Radium Hospital, Oslo University Hospital.…”

Future cancer research priorities in the USA: a Lancet Oncology Commission

“…Unfortunately, this intervention has not been extensively tested and not widely available. 192 Drug–disease or drug–drug interactions (in the case of traditional pharmacological approaches) warrant strengthened efforts to identify new drugs (or non-pharmacological approaches) to effectively mitigate common constellations of symptoms emanating from cancer treatment or the cancer, 193 and to develop mechanistic and predictive models for treatment of adverse effects and symptom risk, taking into account genomics, age, function, and comorbidities.…”